Compare Hinge Health Inc. Class A Common Stock (HNGE) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs SOLAI Limited — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 9.6× SOLAI Limited's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and SOLAI Limited for 42 Days on average.
| HNGE | SLAI | |
|---|---|---|
Market Cap | $8.48B | $880.09M |
Volume | 879,799 | 122,720 |
Sector | Health | Technology |
52-Week High | $105.14 | $21.63 |
52-Week Low | $31.17 | $2.74 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $8.10B | $879.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
SOLAI Limited (SLAI) trades at $3.72 with no recent price movement, showing a mixed technical picture despite a bullish signal from indicators. The company faces severe financial distress with negative gross and net income margins, though it recently beat Q2 2025 EPS expectations. Recent developments include an extraordinary general meeting and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial execution and regulatory risks. While technical indicators suggest potential upside, fundamental weaknesses and delisting proceedings present clear downside risks. Investors should approach with caution given the company's negative profitability and ongoing corporate challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
